MOTS-c vs 5-Amino-1MQ

What is the core difference between MOTS-c and 5-Amino-1MQ?

MOTS-c is a mitochondrial-derived peptide that activates AMPK, while 5-Amino-1MQ is a small-molecule enzyme inhibitor that blocks NNMT.

That single distinction drives everything else. MOTS-c is encoded within mitochondrial DNA and behaves like a signaling peptide that shifts cellular metabolism toward energy production and glucose handling through the AMPK pathway (Lee et al., 2015). 5-Amino-1MQ is a synthetic small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme linked to fat-cell metabolism; blocking it was reported to raise cellular NAD-related activity and reduce fat mass in obese mice (Neelakantan et al., 2018).

Because one is a peptide and one is a small molecule, they belong to different research classes even though both are studied for metabolic questions.

How does MOTS-c work?

MOTS-c works by activating AMPK, a master energy sensor that promotes glucose uptake and fat oxidation.

Lee et al. (2015) identified MOTS-c as a peptide encoded in the mitochondrial genome and showed in mice that it activated the AMPK pathway, improved insulin sensitivity, and protected against diet-induced obesity. The peptide appears to act as a signal that tells cells to burn fuel rather than store it. This work is in the seed of the field, and most MOTS-c evidence to date comes from cell and rodent models rather than large human trials.

For a deeper look at the peptide itself, see the MOTS-c page linked below.

How does 5-Amino-1MQ work?

5-Amino-1MQ works by inhibiting NNMT, an enzyme that influences how fat cells manage energy and NAD-related metabolism.

Neelakantan et al. (2018) reported that 5-Amino-1MQ inhibited NNMT and, in diet-induced obese mice given about 20 mg/kg/day, reduced body weight and fat mass without changing food intake. The proposed idea is that lowering NNMT activity shifts adipose-tissue metabolism and preserves methyl groups and NAD-linked pathways. As with MOTS-c, the evidence base is animal-heavy, and no completed human trials have been published.

MOTS-c vs 5-Amino-1MQ: decision table

The table below summarizes what published research reports. The dose figures are the amounts used in the cited animal studies, not recommendations.

Which has stronger human evidence?

Neither has strong human evidence; both rest mainly on rodent and cell studies.

MOTS-c has a named foundational study in mice (Lee et al., 2015) and has drawn interest for exercise and aging biology, but published human trial data remains limited. 5-Amino-1MQ has preclinical support in diet-induced obese mice (Neelakantan et al., 2018) and no completed human trials that we can cite. Any claim that either compound produces a specific result in people would go beyond what the published record supports. Human data is limited for both.

How do route and side-effect profiles compare?

MOTS-c has been studied as an injectable peptide, while 5-Amino-1MQ is an orally bioavailable small molecule, and formal human safety data is absent for both.

Because peptides like MOTS-c are typically degraded in the gut, the cited research used injection in animals (Lee et al., 2015). 5-Amino-1MQ was described as orally active in mice (Neelakantan et al., 2018), which is often cited as a practical difference between the two. Neither compound has a published human safety profile with defined adverse-event rates, so any side-effect discussion is an extrapolation from animal work rather than from controlled human trials. Questions about personal safety belong with a qualified clinician.